Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus abiraterone/prednisone versus placebo plus abiraterone/prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON50677Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Apalutamide + AAP with Placebo + AAP (2 arms). Primary endpoints: Radiographic progression-free survival, Population pharmacokinetic evaluations and 2 more. Started Sep 2015; status: recruiting.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON50677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50677.